Literature DB >> 24591621

Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.

Jingling Liao1, Chun-Xiang Wu, Christopher Burlak, Sheng Zhang, Heather Sahm, Mu Wang, Zhong-Yin Zhang, Kurt W Vogel, Mark Federici, Steve M Riddle, R Jeremy Nichols, Dali Liu, Mark R Cookson, Todd A Stone, Quyen Q Hoang.   

Abstract

Mutation in leucine-rich-repeat kinase 2 (LRRK2) is a common cause of Parkinson disease (PD). A disease-causing point mutation R1441H/G/C in the GTPase domain of LRRK2 leads to overactivation of its kinase domain. However, the mechanism by which this mutation alters the normal function of its GTPase domain [Ras of complex proteins (Roc)] remains unclear. Here, we report the effects of R1441H mutation (RocR1441H) on the structure and activity of Roc. We show that Roc forms a stable monomeric conformation in solution that is catalytically active, thus demonstrating that LRRK2 is a bona fide self-contained GTPase. We further show that the R1441H mutation causes a twofold reduction in GTPase activity without affecting the structure, thermal stability, and GDP-binding affinity of Roc. However, the mutation causes a twofold increase in GTP-binding affinity of Roc, thus suggesting that the PD-causing mutation R1441H traps Roc in a more persistently activated state by increasing its affinity for GTP and, at the same time, compromising its GTP hydrolysis.

Entities:  

Keywords:  dimer; monomer; neurodegenerative disease; oligomeric states

Mesh:

Substances:

Year:  2014        PMID: 24591621      PMCID: PMC3964117          DOI: 10.1073/pnas.1323285111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins.

Authors:  D P McEwen; K R Gee; H C Kang; R R Neubig
Journal:  Anal Biochem       Date:  2001-04-01       Impact factor: 3.365

2.  Fluorescence approaches to study G protein mechanisms.

Authors:  Dyke P McEwen; Kyle R Gee; Hee C Kang; Richard R Neubig
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

3.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability.

Authors:  Frank H Niesen; Helena Berglund; Masoud Vedadi
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

5.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

Review 6.  LRRK2 in Parkinson's disease: protein domains and functional insights.

Authors:  Ignacio F Mata; William J Wedemeyer; Matthew J Farrer; Julie P Taylor; Kathleen A Gallo
Journal:  Trends Neurosci       Date:  2006-04-17       Impact factor: 13.837

7.  Conformational alterations detected by circular dichroism induced in the normal ras p21 protein by activating point mutations at position 12, 59, or 61.

Authors:  A Valencia; L Serrano; R Caballero; P S Anderson; J C Lacal
Journal:  Eur J Biochem       Date:  1988-07-01

8.  Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.

Authors:  Xianting Li; Yin-Cai Tan; Shibu Poulose; C Warren Olanow; Xin-Yun Huang; Zhenyu Yue
Journal:  J Neurochem       Date:  2007-07-10       Impact factor: 5.372

9.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

10.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

View more
  48 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 2.  In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  Stem Cells Dev       Date:  2018-03-29       Impact factor: 3.272

Review 3.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

4.  Combating Parkinson's disease-associated toxicity by modulating proteostasis.

Authors:  Yangshin Park; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 5.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

6.  Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.

Authors:  Zhiyong Liu; Robert A Galemmo; Kyle B Fraser; Mark S Moehle; Saurabh Sen; Laura A Volpicelli-Daley; Lawrence J DeLucas; Larry J Ross; Jacob Valiyaveettil; Omar Moukha-Chafiq; Ashish K Pathak; Subramaniam Ananthan; Hollis Kezar; E Lucile White; Vandana Gupta; Joseph A Maddry; Mark J Suto; Andrew B West
Journal:  J Biol Chem       Date:  2014-09-16       Impact factor: 5.157

Review 7.  LRRK2 pathobiology in Parkinson's disease.

Authors:  Ian Martin; Jungwoo Wren Kim; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2014-10-10       Impact factor: 5.372

8.  Structure, function, and leucine-rich repeat kinase 2: On the importance of reproducibility in understanding Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-15       Impact factor: 11.205

9.  LRRK2 autophosphorylation enhances its GTPase activity.

Authors:  Zhiyong Liu; James A Mobley; Lawrence J DeLucas; Richard A Kahn; Andrew B West
Journal:  FASEB J       Date:  2015-09-22       Impact factor: 5.191

10.  Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.

Authors:  Md Shariful Islam; Hendrik Nolte; Wright Jacob; Anna B Ziegler; Stefanie Pütz; Yael Grosjean; Karolina Szczepanowska; Aleksandra Trifunovic; Thomas Braun; Hermann Heumann; Rolf Heumann; Bernhard Hovemann; Darren J Moore; Marcus Krüger
Journal:  Hum Mol Genet       Date:  2016-12-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.